UniProt P49760 · PDB · AlphaFold · Substrate: MBP · Clone: catalytic domain aa137-498medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 96.1% | 3.9% | 91.48 | 0.563 |
| 2 | Brigatinib | 96.0% | 4.0% | 82.96 | 0.513 |
| 3 | Defactinib | 94.5% | 5.5% | 92.68 | 0.450 |
| 4 | Pacritinib | 93.6% | 6.4% | 88.64 | 0.452 |
| 5 | Ceritinib | 91.1% | 8.9% | 95.44 | 0.618 |
| 6 | Alectinib | 88.5% | 11.5% | 95.49 | 0.651 |
| 7 | Sunitinib | 85.6% | 14.4% | 91.73 | 0.524 |
| 8 | Capivasertib | 76.0% | 24.0% | 96.48 | 0.644 |
| 9 | Midostaurin | 64.3% | 35.7% | 78.64 | 0.500 |
| 10 | Palbociclib | 62.8% | 37.2% | 98.75 | 0.673 |
| 11 | Gilteritinib | 51.9% | 48.1% | 88.97 | 0.506 |
| 12 | Alpelisib | 46.8% | 53.2% | 97.22 | 0.720 |
| 13 | Bosutinib | 37.9% | 62.1% | 87.22 | 0.555 |
| 14 | Neratinib | 29.5% | 70.5% | 93.18 | 0.597 |
| 15 | Ruxolitinib | 19.4% | 80.6% | 98.25 | 0.592 |
| 16 | Fedratinib | 18.4% | 81.6% | 96.21 | 0.576 |
| 17 | Repotrectinib | 17.9% | 82.1% | 84.21 | 0.608 |
| 18 | Entrectinib | 16.5% | 83.5% | 93.69 | 0.671 |
| 19 | Abrocitinib | 14.2% | 85.8% | 99.50 | 0.581 |
| 20 | Avapritinib | 13.5% | 86.5% | 97.73 | 0.644 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.78
- Epithelial log2(TPM+1): 5.39
- Fold change: -0.62
- Status: No significant change
High-confidence drugs
- Ceritinib — inh 91.1% · KISS 36.65
- Abemaciclib — inh 96.1% · KISS 33.23
- Alectinib — inh 88.5% · KISS 30.02
Selectivity landscape vs inhibition on CLK2
Each point is one of the 92 approved drugs; color = inhibition % on CLK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…